|
Market Closed -
Nasdaq
16:00:00 2026-10-27 EDT
|
Pre-market 09:22:42 | |||
| 159.08 USD | +0.25% |
|
158.64 | -0.28% |
| 10-27 | Gilead Sciences Inc Announces National Agreement for LYVDELZI Seladelpar for Primary Biliary Cholangitis in Canada | CI |
| 10-25 | AstraZeneca Readies New Portfolio of Targeted Cancer Therapies | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | Other Pharmaceuticals | +0.25% | +1.64% | +29.61% | +32.05% | +138.25% | 197B |  | | |
- Stock Market
- Stocks
- GILD Stock
- Charts Gilead Sciences, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
